Pfizer’s coronavirus vaccine candidate enters first phase of US trials

The start of the US trial follows the first jabs administered in Germany last week

Pfizer - Pfizer’s coronavirus vaccine candidate enters first phase of US trials

Pfizer Inc. (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced the first US participants were administered their Covid-19 vaccine candidate.

The trials involve up to 360 healthy subjects into two cohorts, 18-55 and 65-85 years of age.

READ: Coronavirus: what’s happening in the labs of pharma companies worldwide

Another cohort of participants received a jab in Germany last week.

The phase 1/2 of the study determine the safety, immunogenicity and optimal dose level of four vaccine candidates in a single, continuous study.

“The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against COVID-19,” said Albert Bourla, chairman and chief executive of Pfizer.

Shares in Pfizer were flat at US$79.93 in pre-market trading.

Quick facts: Pfizer

Price: 33.83 USD

Market: NYSE
Market Cap: $187.92 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

23 hours, 4 minutes ago

2 min read